ArticleChild and adolescent psychiatry and mental health2026
Attention-deficit/hyperactivity disorder in pediatric cancer survivors: risk and medication use in a nationwide population-based study.
Article in Child and adolescent psychiatry and mental health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundPediatric cancer survivors experience attention or behavioral deficits. This study assessed the risk and medication use of attention-deficit/hyperactivity disorder (ADHD) in pediatric cancer survivors compared with the general population.
methodsUsing nationwide cohort data from Korea’s National Health Insurance Service, we studied a pediatric cancer population (brain tumors [n = 3,517], acute lymphoblastic leukemia [ALL, n = 2,093], and other tumors [n = 30,639]) diagnosed between 2004 and 2011 and 125,663 healthy children. We analyzed the incidence of ADHD, medication patterns, and factors affecting ADHD using the Cox proportional hazards model and logistic regression analysis.
resultsPatients with brain tumors had the highest 10-year ADHD incidence (4.0%, 95% confidence interval [CI] 3.3–4.6) compared with healthy children (2.0%, 95% CI 1.9–2.1), patients with ALL (2.9%, 95% CI 2.2–3.7), and patients with other tumors (2.6%, 95% CI 2.4–2.8). Brain tumor survivors had the highest ADHD risk (hazard ratio [HR] 1.85, 95% CI 1.57–2.17, p < 0.001). Chemotherapy was associated with increased ADHD in children diagnosed at ages 0–3 years (HR 2.89, 95% CI 1.14–7.38, p = 0.03), whereas radiotherapy increased ADHD in patients with ALL (HR 4.10, 95% CI 1.63–10.28, p = 0.003). The use of ADHD medications was significantly higher in younger age groups (0–3 years, HR 2.62, 95% CI 1.98–3.45, p < 0.001; and 4–12 years, HR 3.44, 95% CI 2.30–4.86, p < 0.001) and among brain tumor survivors (HR 1.79, 95% CI 1.32–2.31, p < 0.001). Brain tumor survivors required long-term (> 7 months) ADHD medication (odds ratio 2.06, 95% CI 1.20–3.59, p = 0.01).
conclusionsPediatric cancer survivors, particularly those with brain tumors or diagnosed at a young age, face a higher risk of ADHD and increased use of ADHD medications. Chemotherapy significantly increases the risk of ADHD in infants and toddlers, whereas radiotherapy increases this risk in patients with ALL. Ongoing monitoring and tailored interventions for high-risk groups are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.